English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/59536
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH3 (edelfosine), a proapoptotic agent in tumor cells

AuthorsGajate, Consuelo; Mollinedo, Faustino
Issue Date2002
PublisherBentham Science Publishers
CitationCurrent Drug Metabolism 3(5): 491-525 (2002)
AbstractThe antitumor ether lipid ET-18-OCH3 (edelfosine) is the type of a new class of antineoplastic agents, synthetic analogues of lysophosphatidylcholine, that shows a high metabolic stability, does not interact with DNA and shows a selective apoptotic response in tumor cells, sparing normal cells. Unlike currently used antitumor drugs, ET-18-OCH3 does not act directly on the formation and function of the replication machinery, and thereby its effects are independent of the proliferative state of target cells. Because of its capacity to modulate cellular regulatory and signaling events, including those failing in cancer cells, like defective apoptosis, ET-18-OCH3, beyond its putative clinical importance, is an interesting model compound for the development of more selective drugs for cancer therapy. Although ET-18-OCḢ 3 enhances host defense mechanisms against tumors, its major antitumor action lies in a direct effect on cancer cells, inhibiting phosphatiḋylcholine bioṡynthesis and inducing apoptosis in tumor cells. Recent progress has allowed unravelinġ the molecular mechanism underlying the apoptotic action of ET-18-OCH3, leading to the notion that ET-18-OCH3 is selectively incorporated into tumor cells and induces cell death by intracellular activation of the cell death receptor Fas/CD95. This intracellular Fas/CD95 activation is a novel mechanism of action for an antitumor drug and represents a new way to target tumor cells in cancer chemotherapy that can be of interest as a new framework in designing novel antitumor drugs. ET-18-OCH3 and some analogues are pleiotropic agents that affect additional biomedical important diseases, including parasitic and autoimmune diseases, suggesting new therapeutic indications for these compounds.
Publisher version (URL)https://doi.org/10.2174/1389200023337225
URIhttp://hdl.handle.net/10261/59536
DOI10.2174/1389200023337225
Identifiersdoi: 10.2174/1389200023337225
issn: 1389-2002
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
PROAPOPTOTIC.pdf305,94 kBAdobe PDFThumbnail
View/Open
FigET18.ppt187 kBMicrosoft PowerpointView/Open
Show full item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.